University of Chicago Medicine’s cancer program is the top-ranked in Illinois and No. 12 nationally among cancer hospitals, per U.S. News & World Report. It also holds National Cancer Institute designation, with particular strength in immunotherapy, TIL therapy, CAR-T, theranostics and oligometastases treatment. The program has expanded its cancer network to roughly 20 locations across Illinois and Northwest Indiana, bringing academic-level care closer to patients, and it drew $76 million in research funding and grants in 2025 to support an extensive clinical trial portfolio. The system broke ground on a new cancer pavilion, the first freestanding cancer facility in Illinois, slated to open in 2027. It is also launching the UChicago Medicine Cancer Network’s first national initiative, with AdventHealth Cancer Institute Shawnee Mission in Kansas serving as its first affiliate. The program has also earned its 29th consecutive “A” grade from the Leapfrog Group. Nearly 200 faculty, including more than 40 cancer physicians, were named to Chicago magazine’s 2024 “Top Doctors” list, with additional faculty recognized on its “40 Under 40 in Cancer” list. On the quality front, the program launched an oncology rapid assessment clinic with extended weekly hours to keep patients out of the emergency department, and has partnered with value-based care organizations to deliver bundled, cost-saving care.
